Urgent challenges in quantification and interpretation of brain grey matter atrophy in individual MS patients using MRI

Amiri, Houshang; Sitter, Alexandra de; Bendfeldt, Kerstin; Battaglini, Marco; Wheeler-Kingshott, C; Calabrese, Massimiliano; Geurts, Jeroen J. G.; Rocca, Maria A.; Sastre‐Garriga, Jaume; Enzinger, Christian; Stefano, Nicola De; Filippi, Massimo; Rovira, Àlex; Barkhof, Frederik; Vrenken, Hugo

doi:10.1016/j.nicl.2018.04.023

Cited by 48 publications

(65 citation statements)

References 132 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Numerous factors can have confounding effects on the quantification of brain volume (and its changes) and thereby cause overestimation or underestimation 114 . These factors are discussed below.…”

Section: Evidence Review: Confounding Factorsmentioning

confidence: 99%

MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice

et al. 2020

Self Cite

View full text Add to dashboard Cite

Early evaluation of treatment response and prediction of disease evolution are key issues in the management of people with multiple sclerosis (MS). In the past 20 years, MRI has become the most useful paraclinical tool in both situations and is used clinically to assess the inflammatory component of the disease, particularly the presence and evolution of focal lesions — the pathological hallmark of MS. However, diffuse neurodegenerative processes that are at least partly independent of inflammatory mechanisms can develop early in people with MS and are closely related to disability. The effects of these neurodegenerative processes at a macroscopic level can be quantified by estimation of brain and spinal cord atrophy with MRI. MRI measurements of atrophy in MS have also been proposed as a complementary approach to lesion assessment to facilitate the prediction of clinical outcomes and to assess treatment responses. In this Consensus statement, the Magnetic Resonance Imaging in MS (MAGNIMS) study group critically review the application of brain and spinal cord atrophy in clinical practice in the management of MS, considering the role of atrophy measures in prognosis and treatment monitoring and the barriers to clinical use of these measures. On the basis of this review, the group makes consensus statements and recommendations for future research.

show abstract

Section: Evidence Review: Confounding Factorsmentioning

confidence: 99%

MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…In the past decade, cortical gray matter (GM) pathology has been established as an important contributing mechanism in this debilitating disorder (Fisher, Lee, Nakamura, & Rudick, ; Geurts & Barkhof, ; Roosendaal et al, ). GM atrophy can be quantified in an automated fashion in vivo using MRI (Amiri et al, ) and most likely reflects a diffuse reduction in cortical neuronal density, axonal density, and neuronal size (Popescu et al, ). This process has been shown to be associated with cortical lesion volume (Calabrese et al, ) and is thought to be, at least in part, the consequence of a pathogenic process driven from pial lesions (Mainero et al, ).…”

Section: Introductionmentioning

confidence: 99%

Longitudinal patterns of cortical thinning in multiple sclerosis

Tsagkas

Chakravarty

Gaetano

et al. 2020

Human Brain Mapping

View full text Add to dashboard Cite

In multiple sclerosis (MS), cortical atrophy is correlated with clinical and neuropsychological measures. We aimed to examine the differences in the temporospatial evolution of cortical thickness (CTh) between MS-subtypes and to study the association of CTh with T2-weighted white matter lesions (T2LV) and clinical progression. Two hundred and forty-three MS patients (180 relapsing-remitting [RRMS], 51 secondary-progressive [SPMS], and 12 primary-progressive [PPMS]) underwent annual clinical (incl. expanded disability status scale [EDSS]) and MRI-examinations over 6 years.T2LV and CTh were measured. CTh did not differ between MS-subgroups. Higher total T2LV was associated with extended bilateral CTh-reduction on average, but did not correlate with CTh-changes over time. In RRMS, CTh-and EDSS-changes over time were negatively correlated in large bilateral prefrontal, frontal, parietal, temporal, and occipital areas.In SPMS, CTh was not associated with the EDSS. In PPMS, CTh-and EDSS-changes over time were correlated in small clusters predominantly in left parietal areas. Increase of brain

show abstract

“…Atrophy in MS is often considered to be the result of extensive axonal transection and demyelination [21][22][23]. The contribution of neuroglia may be less clear; reactive gliosis has the potential to mask considerable tissue loss in WM lesions [24,25].…”

Section: Introductionmentioning

confidence: 99%

Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options

Andravizou

Dardiotis

Artemiadis

et al. 2019

Autoimmun Highlights

112

View full text Add to dashboard Cite

Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system characterized by focal or diffuse inflammation, demyelination, axonal loss and neurodegeneration. Brain atrophy can be seen in the earliest stages of MS, progresses faster compared to healthy adults, and is a reliable predictor of future physical and cognitive disability. In addition, it is widely accepted to be a valid, sensitive and reproducible measure of neurodegeneration in MS. Reducing the rate of brain atrophy has only recently been incorporated as a critical endpoint into the clinical trials of new or emerging disease modifying drugs (DMDs) in MS. With the advent of easily accessible neuroimaging softwares along with the accumulating evidence, clinicians may be able to use brain atrophy measures in their everyday clinical practice to monitor disease course and response to DMDs. In this review, we will describe the different mechanisms contributing to brain atrophy, their clinical relevance on disease presentation and course and the effect of current or emergent DMDs on brain atrophy and neuroprotection. which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

show abstract

Urgent challenges in quantification and interpretation of brain grey matter atrophy in individual MS patients using MRI

Cited by 48 publications

References 132 publications

MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice

MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice

Longitudinal patterns of cortical thinning in multiple sclerosis

Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options

Contact Info

Product

Resources

About